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1. Introduction
  Histamine has incredible influence over an assortment of 
pathophysiological processes through the activation of four 
receptors: H1, H2, H3 and H4, and is known to participate 
in allergy, inflammation, secretion of gastric acid, 
immunomodulation and neurotransmission[1]. Moreover, 
histamine immunobiology pertaining to histamine receptors 
is elementary in contrast to increasing frequency of 
allergic diseases. Accumulating evidences have also been 
postulated its important role in other pathological conditions 
such as increased level in bronchoalveolar lavage fluid 
from patients with allergic asthma, and this increase is 
negatively correlated with airway function. An increase in 
histamine level has been observed in skin and plasma of 
patients of atopic dermatitis (AD), chronic urticaria (CU), 
multiple sclerosis (MS) and in psoriatic skin[2]. Histamine 
receptors (H1, H2, H3 and H4) transducing extracellular 
signals through different G-proteins: Gq/11 for H1, Gαs  for 
H2, Gi/o for H3 and H4-receptors[1]. Specific activation or 
inhibition of histamine receptors has led to a tremendous 
increase in the knowledge of the roles of histamine in 
physiology and pathology of disease conditions[1, 3]. 
Histamine receptors have been revealed to increase delayed 
hypersensitivity and antibody mediated immune responses 
in several pathological processes regulating several 
essential events in allergies and autoimmune diseases in 
experimental animals, especially in knock out mice (either 
H1- or H2-deficient)[4-6].
  Thus, after a century of histamine discovery, the existing 
literature has provided intensive knowledge about its 
synthesis, metabolism, receptors, signal transduction, 
and physiological and pathological effects. However, 
the roles of the complex interrelationship and cross talk 
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by histamine and its receptors on antibody generation in 
immunobiology remained to be elucidated. Our recent 
studies have confirmed that histamine has a short-term 
effect on antibody generation (until its presence in the 
body), and the antibody generation titer in vivo was affected 
by the concentration of histamine[7, 8]. Notably, H1-specific 
antagonist tripelennamine inhibited histamine binding 
in T-helper1 (Th1) but not in T-helper2 (Th2) cells and 
demonstrated predominant H1 expression on Th1 cells. 
Neither H2-antagonist ranitidine nor H3-antagonist/H4-
partial agonist clobenpropit had any impact on histamine 
binding to Th1 cells. H1-receptors and H2-receptors are 
regulated by specific cytokines present in the immune 
system, and the expression of H1 on Th1 cells and H2 on 
Th2 cells were confirmed by antibodies generated against 
the H1- and H2-receptor[9].
  Therefore, our present comparative study account for 
exploration of the regulatory mechanisms in the control of 
immune process through effector cells derived histamine, 
exogenous histamine and histamine H1-, H2-, H3- & H4-
receptors-antagonist in immunomodulation in rabbit model. 
2. Materials and methods
2.1. Experimental design
  To evaluate the systemic antibody response, 144 (72 male 
and 72 female) New Zealand adult healthy rabbits of either 
sex weighing 1.63依0.36 kg were randomized equally into 
eight treatment groups, i.e. 18 rabbits (9 male and 9 female) 
in each group. 
  Control group: Group I (negative control) remained non-
immunized and received only vehicle (sterile distilled water, 
1 mL/kg 伊 b.i.d.). Group II was vehicle (sterile distilled 
water, 1 mL/kg 伊 b.i.d.) treated and immunized as a positive 
control.  
  Experimental group: Group III was histamine-treated 
and immunized, group IV was H1R-antagonist-treated 
and immunized, group V was H2R-antagonist-treated and 
immunized, group VI was H3R-antagonist-treated and 
immunized, group VII was H4R-antagonist-treated and 
immunized, and group VIII was dimethyl sulphoxide treated 
(DMSO-treated) (control group for H4R-antagonist) and 
immunized.  
  The animals were housed in well-maintained animal 
facility at central animal house, J. N. Medical College 
& Hospital, Aligarh Muslim University, Aligarh, in 
the Bioresources unit under a 12 hr light/dark cycle, 
temperature of (22±2) 曟 and were allowed free access to 
standard laboratory diet including green vegetables and tap 
water until experimentation. Each animal was used only 
once. All studies were carried out during the light cycle 




  All materials were obtained from the following 
manufacturers: Monoclonal-anti-rabbit-immunoglobulins-
horseradish peroxidase (HRP) conjugate and monoclonal-
anti-rabbit-IgG-HRP conjugate from Sigma (USA), anti-
rabbit-IgM-HRP conjugate from G Biosciences from 
Maryland heights (USA), tetramethyl benzidine (TMB) and 
TMB diluent from J. Mitra and Co. (India), Polystyrene 
MaxiSorp microtitre flat and round bottom ELISA plates from 
NUNC (Denmark), Glutaraldehyde solution from Central 
Drug House (India), Skim milk from Nestle India Ltd. (New 
Delhi), and DMSO was obtained from Qualigen, Glaxo, India. 
All chemicals were of analytical grade.
2.3. Drugs
  Following drugs were used: histamine dihydrochloride from 
Himedia laboratories Pvt Limited, India; H1R-antagonist: 
Avil® (pheniramine maleate) in injection I.P. by Unimark 
Remedies, India and H2R-antagonist: Rantac® (ranitidine 
hydrochloride) in injection I.P. by J. B. Chemicals and 
Pharmaceuticals, India; H3R-antagonist (iodophenpropit 
dihydrobromide) was kindly donated by Tocris Bioscience, 
Tocris Cookson Ltd., United Kingdom; and H4R-antagonist 
(JNJ 7777120) from Sigma (USA). 
2.4. Doses
 Histamine (100 毺g/kg伊 b.i.d.) was administered through 
subcutaneous (s.c.), and pheniramine maleate (10 mg/
kg伊 b.i.d.), ranitidine hydrochloride (10 mg/kg 伊b.i.d.), 
iodophenpropit dihydrobromide (1 毺g/kg伊 b.i.d.), JNJ 
7777120 (10 毺g/kg伊b.i.d.) and DMSO (1 mL/kg 伊 b.i.d.) 
were administered through intramuscular (i.m.); starting 
from three days prior to immunization until 7 days after 
immunization. All doses were referred to the weight of the 
salts used.  
2.5. Antigen 
  Sheep blood diluted 1:1 in sterile Alsevier’s solution was 
obtained from Department of Microbiology, J. N. Medical 
College & Hospital, A.M.U., Aligarh, and washed with PBS 
(10 mM sodium phosphate buffer containing 150 mM NaCl, 
pH-7.4) thrice by centrifugation. The cell suspensions 
were adjusted to the desired concentration in terms of 
hemoglobin, lysis of a 1% sheep red blood cells (SRBC) 
suspension (2 伊 108 cells/mL) with 14 volumes of 0.1% 
Na2CO3 develops an optical density of 0.135 at 541 nm in 
a spectrophotometer (Systronics, UV visible double beam 
spectrophotometer-2101, India), as described Franzl[10]. 
Finally the concentration was adjusted to 5% (1伊109 cells/
mL) in PBS for immunization before use. 
 
2.6. Immunization of rabbits
  The rabbits in groups II-VIII were immunized 
intravenously via marginal ear vein with 1 mL of 5% (1伊 109 
cells/mL)  SRBC in PBS. 
2.7. Sample collection 
  To determine the systemic antibody response, blood 
samples were collected from rabbits through the marginal 
ear veins into labelled sterile bottles prior to immunization 
(day 0), as well as on days 7, 14, 21, 28 and 58 post-
immunization. Blood samples were kept at room temperature 
for 2 hr and then at 4 曟 overnight. Blood samples were 
centrifuged for 10 minutes at 580 伊 g, and serum was isolated 
and heated at 56 曟 for 30 minutes to inactivate complement 
proteins and stored in aliquots containing sodium azide as 
preservative at -20 曟 till tested further[11].
2.8. Serological analysis 
2.8.1. ELISA using whole SRBC
  The whole SRBC-ELISA[7,8,12,13] was used to determine 
anti-SRBC-Igs, anti-SRBC-IgM and anti-SRBC-IgG response. 
In brief, polystryrene MaxiSorp immunoplates were coated 
with SRBC suspension (5 伊106/100 毺L PBS). The plates were 
held overnight at 4 曟. Each sample was coated in duplicate 
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and half of the plates served as controls devoid of antigen 
coating. Without disturbing the cell layer, 20 毺L  of 
1.8% glutaraldehyde solution was then gently added to 
plates inoculated with SRBC and the plates were held at 25 曟 
for 30 minutes. Unbound SRBC was washed four times 
with 200 毺L of PBS and non-specific binding sites were 
blocked with 1% fat-free milk in PBS for 120 minutes at 
37 曟. After incubation, the plates were washed four times 
with 200 毺L of PBS. Each rabbit serum diluted 1:100 in 
PBS (100 毺L/well) was adsorbed for 90 minutes at 37 曟, and 
then overnight at 4 曟 followed by washing as earlier. The 
secondary antibody, HRP conjugated monoclonal-anti-
rabbit-immunoglobulins, monoclonal-anti-rabbit-IgM and 
monoclonal-anti-rabbit-IgG was then added (100 毺L/well) 
in respective plates and incubated at 37 曟 for 60 minutes. 
The washing stage was repeated as before and 100 毺L/well 
TMB substrate was added and the plates were incubated at 
25 曟 for 60 minutes. The enzymatic reaction was stopped 
by adding 50 毺L/well of 5% H2SO4. The absorbance (A) was 
determined at 405 nm on an automatic ELISA plate reader 
(Micro scan MS5608A, ECIL, India). Each rabbit serum 
sample was run in duplicate. The control wells were treated 
similarly but were devoid of antigen. Results were expressed 
as a mean of Atest- control. 
2.9. Statistical analysis
  Data were summarized as Mean依SD. Groups were compared 
by using repeated measures (subjects within groups) two 
way analysis of variance (ANOVA) followed by Newman-
Keuls post hoc test. A two-tailed (毩= 2) probability P<0.05 
was considered to be statistically significant. Analyses were 
performed on SPSS for windows (version 15.0, Inc., Chicago, 
IL). 
3. Results
  To evaluate the effects of histamine receptors-antagonist 
on the immunomodulation, antibody-mediated responses 
to SRBC were assessed. Total serum immunoglobulins (Igs), 
total immunoglobulin-M (IgM) and total immunoglobulin-G 
(IgG) generation profiles were studied in vivo in eight 
experimental groups at days 0 (pre-immunization, pre-I), 7, 
14, 21, 28 and 58 (post-immunization,  post-I).
3.1. Profile of total anti-SRBC-immunoglobulins (Igs) 
production
  The profile of total anti-SRBC-Igs titer was studied by 
whole SRBC-ELISA method[7,8,12,13] (Figure 1). No anti-
SRBC-Igs response was detected in all experimental groups 
(negative control, positive control and drug treated) at day 
0 (pre-I). There was an initial increase and subsequent 
decrease in total serum Igs titer over a time span of 58 days 
in all the groups. The detailed summary of statistically 
analyzed Igs production by two way  analysis of variance 
(ANOVA) followed by Newman-Keuls post hoc test is shown 
in Figure 1. By day 7 post-I, anti-SRBC-Igs titer was 
significantly high, however it obtained a peak at day 14, and 
by days 21, 28 and 58 post-I. There was a gradual decrease 
or a plateau in all experimental groups as compared to 
histamine-treated and H3R-antagonist-treated groups 
(Figure 1). More extensive evaluation revealed that anti-
SRBC-Igs raised steeply up to 7 days post-I, and there 
was a decrease in histamine-treated and H3R-antagonist-
treated groups as compared to all other experimental groups.
  Histamine-treated group showed initial suppression 
(P< 0.01) (as opposed to H3R-antagonist-treated group) 
and enhancement (P< 0.01) (as compared to H1R-,H2R-
and H4R-antagonists-treated, positive control and DMSO-
treated groups) of anti-SRBC-Igs generation titer at day 
7 post-I, and later suppression was observed in the anti-
SRBC-Igs production titer during the whole study as 
compared to all other experimental groups at days 14, 
21, 28 & 58 post-I except H1R-antagonist-treated group 
(histamine showed enhanced Igs generation titer at days 28 
and 58 post-I).  
Figure 1. SRBC-specific immunoglobulins (Igs) production titers in 
H1R-, H2R-, H3R- & H4R-antagonist-treated rabbits by whole 
SRBC-ELISA method in duplicate 1:100 diluted sera. 
The results demonstrate Mean±SD of three experiments each with 
six rabbits. Two-way ANOVA followed by Newman-Keuls post hoc 
test revealed that the effect of treatments (F=3 608.816, DF=7 136; 
P<0.01) and days (F=72 124.468, DF=5 680; P<0.01) on SRBC were 
statistically significant.  The interaction (treatment伊days) effect of 
(F=3 896.230, DF=35 680; P<0.01) these on SRBC were also found to 
be significant. 
  H3R-antagonist-treated group showed significant (P< 
0.01) enhancement of total anti-SRBC-Igs at days 7- and 14 
post-I as compared to all other experimental groups, while 
it showed significant (P< 0.01) suppression as compared to 
H2R-antagonist-and H4R-antagonist-treated groups at 
days 21, 28 & 58 post-I (whereas significant suppression was 
noticed as compared to positive control & DMSO-treated at 
day 21 post-I). This group further demonstrated significant 
(P< 0.01) enhancement as opposed to H1R-antagonist-
treated and histamine-treated at days 21, 28 & 58 post-I, 
and also positive control & DMSO-treated groups at days 28 
and 58 post-I. The anti-SRBC-Igs generation titer in H4R-
antagonist-treated group showed significant suppression (P< 
0.01) as compared to H3R-antagonist- & histamine-treated 
groups; however it showed similarity to DMSO-treated 
and positive control group at day 7 post-I. Furthermore, 
this group showed significant (P< 0.01) enhancement as 
opposed to H2R-antagonist- and H1R-antagonist-treated 
groups at days 7 post-I. At day 14 post-I, H4R-antagonist 
showed further suppression of anti-SRBC-Igs generation 
titer as opposed to H3R-antagonist-treated, positive control 
and DMSO-treated; while it demonstrated enhanced Igs 
titer as compared to H1R-antagonist-, H2R-antagonist- 
and histamine-treated groups. Furthermore, this group 
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showed enhancement of anti-SRBC-Igs generation titer 
as opposed to all other experimental groups at days 21, 28 
and 58 post-I. H4R-antagonist- and H2R-antagonist-
treated groups demonstrated similar profile of anti-SRBC-
Igs generation titer; however H4R-antagonist-treated group 
showed enhanced profile as opposed to H2R-antagonist-
treated group (Kindly refer to Figure 1 for statistical 
analysis). Moreover, H1R-antagonist-treated rabbits 
showed suppression of anti-SRBC-Igs level at days 7, 14, 
21, 28 and 58 post-I in comparison to all other experimental 
groups (P< 0.01) except histamine-treated group (whereas 
this group demonstrated enhancement of total serum anti-
SRBC-Igs levels at days 14 and 21 post-I which were 
found statistically significant). H1R-antagonist-treated 
rabbits showed significant (P< 0.01) suppression of total 
anti-SRBC-Igs as opposed to that of H2R-,H3R-&H4R-
antagonist-treated groups and positive control rabbits 
(Figure 1).  
3.2. Profile of anti-SRBC-immunoglobulin-M (IgM) 
production
  Anti-SRBC-IgM was determined by whole SRBC-ELISA 
method [7,8,12,13] (Figure 2). No anti-SRBC-IgM response 
was observed in all experimental groups (negative control, 
positive control and HRs-antagonist-treated) at day 0- 
pre-I; however there was an initial increase and then 
gradual decrease in serum-IgM titer over time in all the 
groups. The detailed summary of statistically analyzed IgM 
production by two way analysis of variance (ANOVA) followed 
by Newman-Keuls post hoc test is shown in Figure 2. By 
day 7 post-I, the IgM titer increased and obtained highest 
peak, but by days 14, 21, 28, and 58 post-I there was a 
gradual decrease in all experimental groups (except H1R-
antagonist-treated, H2R-antagonist-treated and H3R-
antagonist-treated groups, where the highest peak was 
obtained at day 14 post-I and then there was a gradual 
decrease). 
  Histamine-treated group showed initial suppression 
(as opposed to H3R-antagonist-treated group) and 
enhancement (as compared to H1R-,H2R-&H4R-antagonist 
-treated, positive control and DMSO-treated groups) of 
anti-SRBC-IgM generation titer at day 7 post-I, and later 
suppression was noticed in the anti-SRBC-IgM production 
titer during the whole study as compared to all other 
experimental groups at days 14, 21, 28 & 58 post-I except 
H1R-antagonist- and DMSO-treated group (histamine 
showed significant enhanced IgM generation titer at days 
28 and 58 post-I as compared to H1R-antagonist-treated 
group, while histamine showed similar IgM production level 
to DMSO-treated group at days 28 and 58 post-I). 
  H3R-antagonist-treated group showed significant (P< 
0.01) enhancement of total anti-SRBC-IgM at days 7 
post-I as compared to all the experimental groups, while 
it showed significant (P<0.01) suppression as compared 
to H4R-antagonist-treated groups at days 14, 21, 28 & 58 
post-I and also showed significant (P<0.01) suppression 
as compared to H2R-antagonist-treated group at days 14, 
21 & 28 post-I, whereas H3R-antagonist group showed 
suppression as compared to positive control group at day 21 
post-I. This group further demonstrated significant (P<0.01)
enhancement as opposed to H1R-antagonist-treated and 
histamine-treated at days 14, 21, 28 & 58 post-I, and also 
positive control & DMSO-treated groups at days 21, 28 & 
58 post-I. The anti-SRBC-IgM generation titer in H4R-
antagonist-treated group showed suppression as compared 
to positive control & DMSO-treated and also significant 
suppression (P<0.01)as compared to H3R-antagonist- & 
histamine-treated groups. Furthermore, this group showed 
significant (P<0.01)) enhancement as opposed to H1R-and 
H2R-antagonist-treated groups at days 7 post-I. Moreover 
at day 14, 21, 28 & 58 post-I, H4R-antagonist further 
showed significant (P<0.01)enhancement of anti-SRBC-
IgM generation titer as opposed to all other experimental 
groups (Figure 2). H4R-antagonist- and H2R-antagonist-
treated groups demonstrated similar profile of anti-SRBC-
IgM generation titer; however H4R-antagonist-treated group 
showed enhanced profile as opposed to H2R-antagonist-
treated group.  
Figure 2. SRBC-specific immunoglobulin-M (IgM) production titers 
in H1R-, H2R-, H3R- & H4R-antagonist-treated rabbits by whole 
SRBC-ELISA method in duplicate 1:100 diluted sera. 
The results demonstrate Mean±SD of three experiments each with 
six rabbits. Two-way ANOVA followed by Newman-Keuls post hoc 
test revealed that the effect of treatments (F=2 167.238, DF=7 136; 
P<0.01) and days (F=16 405.067, DF=5 680; P<0.01) on SRBC were 
statistically significant. The interaction (treatment伊days) effect of 
(F=642.525, DF=35 680; P<0.01) these on SRBC were also found to 
be significant. 
  Moreover, H1R-antagonist-treated rabbits showed 
suppression of anti-SRBC-IgM level at days 7, 14, 21, 28 and 
58 post-I in comparison to all other experimental groups 
except histamine-treated group (this group demonstrated 
enhancement of total serum anti-SRBC-IgM level at days 
14 and 21 post-I which were found statistically significant). 
H1R-antagonist-treated rabbits showed significant (P<0.01) 
suppression of total anti-SRBC-IgM as opposed to that of 
H2R-,H3R-&H4R-antagonist-treated and positive control 
rabbits (Figure 2). 
3.3. Profile of anti-SRBC-immunoglobulin-G (IgG) 
production 
  The profile of total anti-SRBC-IgG titer was also studied by 
whole SRBC-ELISA method[7,8,12,13] (Figure 3). The detailed 
summary of statistically analyzed IgG production by two way 
analysis of variance (ANOVA) followed by Newman-Keuls 
post hoc test is shown in Figure 3. More extensive evaluation 
revealed that anti-SRBC-IgG in histamine-treated groups 
raised steeply up to 7 days post-I as compared to positive 
control, DMSO-treated and H1R-,H2R-&H4R-antagonist 
groups, but showed suppression as opposed to H3R-
antagonist-treated rabbits. By days 14, 21, 28 and 58 
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post-I there was a significant(P<0.01) decrease in anti-
SRBC-IgG levels in histamine-treated as compared to all 
other experimental groups except H1R-antagonist-treated 
(whereas it showed enhancement of IgG as opposed to H1R-
antagonist-treated at day 14 post-I) and this was found 
statistically significant (Figure 3). H3R-antagonist-treated 
group showed significant(P<0.01) enhancement of total 
anti-SRBC-IgG at days 7 post-I as compared to all other 
experimental groups, while it showed significant(P<0.01)
suppression as compared to H4R-and H2R-antagonist-
treated groups, positive control and DMSO-treated groups 
and also showed significant (P<0.01) enhancement as 
compared to H1R-antagonist- & histamine-treated 
groups at days 14 post-I. This group further demonstrated 
enhancement as opposed to all other experimental groups 
except H4R-antagonist-treated group (whereas it showed 
suppressed IgG level) at days 21, 28 & 58 post-I). The anti-
SRBC-IgG generation titer in H4R-antagonist-treated group 
showed significant suppression as compared to histamine- 
& H3R-antagonist-treated groups. However, it showed 
similar IgG production level near to positive control & 
DMSO-treated and also H1R-and H2R-antagonist-treated 
groups at day 7 post-I. H4R-antagonist-treated group 
further demonstrated similar IgG generation titer near to 
positive control & DMSO-treated, while it showed significant 
(P<0.01) enhancement as compared to histamine- & H1R/
H3R-antagonist-treated groups at day 14 post-I. Moreover 
at day 21, 28 & 58 post-I, H4R-antagonist further showed 
significant (P<0.01) enhancement of anti-SRBC-IgG 
generation titer as opposed to all other experimental groups 
(Figure 3).
Figure 3. SRBC-specific immunoglobulin-G (IgG) production titers 
in H1R-, H2R-, H3R- & H4R-antagonist-treated rabbits by whole 
SRBC-ELISA method in duplicate 1:100 diluted sera. 
The results demonstrate Mean±SD of three experiments each with 
six rabbits. Two-way ANOVA followed by Newman-Keuls post hoc 
test revealed that the effect of treatments (F=2 425.731, DF=7 136; 
P<0.01) and days (F=8 166.595, DF=5 680; P<0.01) on SRBC were 
statistically significant.  The interaction (treatment伊days) effect of 
(F=507.794, DF=35 680; P<0.01) these on SRBC were also found to 
be significant. 
  H2R-antagonist-treated and H4R-antagonist-treated 
rabbits showed similar anti-SRBC-IgG generation titer 
at days 7 & 14 post-I, while on further analysis, H2R-
antagonist-treated group showed significant enhancement 
as compared to histamine-treated & H1R-antagonist-
treated group and also demonstrated significant suppression 
as compared to H4R-antagonist-, H3R-antagonist-treated 
& positive control groups at days 21, 28 & 58 post-I (Figure 
3).  
  H1R-antagonist-treated rabbits showed significant 
(P<0.01) suppression of anti-SRBC-IgG level at days 7, 14, 
21, 28 and 58 post-I in comparison to all other experimental 
groups except histamine-treated group and demonstrated 
enhancement of total serum anti-SRBC-IgG level at days 21, 
28 & 58 post-I (Figure 3).  
4. Discussion
  Histamine receptors are distributed in all parts of body and 
modulate several physiological and pathological reactions 
both in vivo and in vitro by the activation on releasing the 
histamine[1] and it has also been well documented that 
histamine shows the agonist properties of their receptors 
(H1R, H2R, H3R & H4R)[1,2,9]. Besides, histamine also 
modulates immunological reactions and directly affects 
B-cell antibody production as a co-stimulatory receptor 
on B-cells[3,6-8,14,15]. It is also documented in mice that 
histamine enhances anti-IgM induced proliferation of 
B-cells, which abolished in H1R deleted mice. In H1R-
deleted mice antibody production against a T-cell 
independent antigen-TNP-Ficoll is decreased[16], suggesting 
an important role of H1R signaling in response triggered 
from B-cell receptors. A different pattern of antibody 
responses to T-cell dependent antigens like ovalbumin 
showed that H1R-deleted mice produced high ovalbumin-
specific IgG1 and IgE in comparison to wild type mice[9].
  Keeping in view the above facts, especially the paucity of 
literature (i.e., immunomodulatory role of histamine H1-, 
H2-, H3- and H4-receptors), defining the correlation of 
histamine receptors-antagonists in immune regulation & 
modulation and the fragmentary literature of histamine 
receptors (H1R, H2R, H3R and H4R) describing existing 
immunomodulatory role of histamine and histamine 
receptors in vivo system, the present study was proposed.
  Therefore, the comparative study explored total serum 
anti-SRBC-Igs, IgM and IgG generation profile against 
SRBC (a T-cell-dependent test antigen)[13,17] in negative 
control (untreated) and treated groups (positive control, 
H1R-antagonist, H2R-antagonist, H3R-antagonist, H4R-
antagonist, histamine, and DMSO-treated-experimental 
groups) in healthy albino rabbits. The study reveals that 
H1R-, H2R-, H3R- & H4R-antagonists-treated rabbits were 
characterized by a marked deviation of the immune response 
as compared to control rabbits. 
  Our recent studies demonstrated that the histamine 
released from immunological stimuli from effector cells in 
vivo[1], could influence a detectable antibody response to 
SRBC[7,8]. These studies showed that the histamine treated-
rabbits presented immunopotentiating properties by 
enhancing the anti-SRBC-antibodies levels as compared to 
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positive control group.
  The comparative study, with the presence of H1-, H2-, 
H3- & H4-antagonist in the body, in vivo immunoregulatory 
processes demonstrated enhanced generation profile of 
anti-SRBC-antibody (total-anti-SRBC-Igs, IgM and IgG) 
in H3R-antagonist-treated rabbits as compared to positive 
control rabbits, while H4R-antagonist, H2R-antagonist- 
and H1R-antagonist-treated rabbits revealed suppressed 
generation profile of total-anti-SRBC-Igs, IgM and IgG 
as compared to positive control rabbits. Whereas, study 
on further metabolism of antagonists in the body showed 
enhanced anti-SRBC-Igs, IgM and IgG generation profile 
in H4R-, H3R- & H2R-antagonist-treated rabbits (H4R- 
showed more marked immune modulation as compared 
to H3R- & H2R-) as compared to positive control rabbits. 
H1R-antagonist-treated rabbits showed suppressed 
antibody generation profile overall the study period as 
compared to other experimental groups. Furthermore, the 
effects of histamine & H1R-H4R antagonist disappeared on 
the antibody generation profile bringing them in the range 
of control antibody level at the final phase of study due to 
complete metabolism.
  To conclude, our results provide evidence that histamine 
receptors (H1R, H2R, H3R & H4R) on antagonized have 
important roles in modulation of antibody generation, in 
which H1R has a dominant suppressive role as compared 
to H2R and H4R (H2R revealed more marked suppressive 
capability as compared to H4R). Conversely, H3R has a 
dominant enhancing role, this receptor thus has a regulatory 
role for histamine receptors (H1, H2 and H4) and an auto-
regulatory role for itself in immuno-biological system. 
To the best of our knowledge, this is the first report 
describing the potential comparative immunomodulatory 
and immunoregulatory roles of H1-, H2-, H3- and H4- 
receptors.
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